The first FDA-approved to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
New indication joins a series of single-agent and combination treatments for various cancers.
How HHS efforts to increase competition could hurt patients.
A new study suggests that the FDA and manufacturers did not act when evidence emerged that potentially lethal fentanyl products were being inappropriately prescribed to patients.
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.
A first-of-its kind study examined the association between using medication to treat OUD and mortality in patients who had a nonfatal opioid overdose.
FDA’s plan to evaluate gene therapies’ impact on surrogate end points is amping up concerns among payers. Here’s why